Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents
In: Blood, Jg. 141 (2023-06-01), Heft 22, S. 2727-2737
Online
serialPeriodical
Zugriff:
•OS for relapsed/refractory Hodgkin lymphoma after autologous HCT has improved after the approval of BV and the PD-1 inhibitors.•PD-1 inhibitor-based salvage regimens before autologous HCT improved PFS in multivariable analysis.
Titel: |
Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents
|
---|---|
Autor/in / Beteiligte Person: | Spinner, Michael A. ; Sica, R. A. ; Tamaresis, John S. ; Lu, Ying ; Chang, Cheryl ; Lowsky, Robert ; Frank, Matthew J. ; Johnston, Laura J. ; Miklos, David B. ; Muffly, Lori S. ; Negrin, Robert S. ; Rezvani, Andrew R. ; Shiraz, Parveen ; Shizuru, Judith A. ; Weng, Wen-Kai ; Binkley, Michael S. ; Hoppe, Richard T. ; Advani, Ranjana H. ; Arai, Sally |
Link: | |
Zeitschrift: | Blood, Jg. 141 (2023-06-01), Heft 22, S. 2727-2737 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 0006-4971 (print) ; 1528-0020 (print) |
DOI: | 10.1182/blood.2022018827 |
Sonstiges: |
|